Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly toxic, and typically fail clinical trials. One alternative app...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiawei, Gan, Yichao, Li, Hongzhi, Yin, Jie, He, Xin, Lin, Liming, Xu, Senlin, Fang, Zhipeng, Kim, Byung-wook, Gao, Lina, Ding, Lili, Zhang, Eryun, Ma, Xiaoxiao, Li, Junfeng, Li, Ling, Xu, Yang, Horne, David, Xu, Rongzhen, Yu, Hua, Gu, Ying, Huang, Wendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122913/
https://www.ncbi.nlm.nih.gov/pubmed/35595767
http://dx.doi.org/10.1038/s41467-022-30264-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122913/
https://www.ncbi.nlm.nih.gov/pubmed/35595767
http://dx.doi.org/10.1038/s41467-022-30264-0

Ejemplares similares